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Abstract
Foot-and -mouth disease to pigs is serious recently around the world. “Vaccination prevention” is still an important
policy. OIE specifies 10,000 TCID50(0.2 ml) of virulent virus for challenge test in pigs to test the potency of FMD
vaccine by intradermal route inoculating the virus in the heel bulbs of one foot or by intramuscular route adminis-
tering into one site of the neck behind the ear. Convenience and speediness are available in the process of
potency test of commercial FMD vaccine. We selected the route of “administering into one site of the muscular
part of the neck behind the ear” because of convenience and speediness. However, it was difficult to infect control
pigs even up to 100,000TCID50, so we changed the challenged virus from cell-passaged strain to suckling mice-
passaged one, measured its PID50 (pigs median infected dose) and defined the virus challenge dose as 1000PID50.
Meanwhile, we arranged the number of control pigs from two to three for easy evaluation.
Findings
Foot-and-mouth disease (FMD) is an extremely conta-
gious viral disease of cloven-hoofed domesticated as well
as wild animals and has a great potential for causing
severe economic loss. The causal agent, FMD virus
(FMDV), is a member of the genus Aphthovirus in the
family Picornaviridae and occurs as seven distinct sero-
types throughout the world: A, O, C, Asia1 and South
African Territories (SAT) 1-3. Vaccination is the most
important control and eradication strategy for FMD,
especially the oil-adjuvant vaccine in developing coun-
tries [1-4]. The different processes for preparing vac-
cines against viral diseases are comprised by a sequence
of steps which, although different in accordance with
particular virus and processes selected, may be classified
as follows: virus production, virus inactivation and vac-
cine formulation.
In recent years, the pigs infected with FMD have been
reported around the Chinese mainland, such as Chinese
Taipei, Chinese Hong Kong [5-9]. Furthermore, import of
vaccines are not only expensive, they are not always suita-
ble. Therefore research into vaccine development and
improvement is vital. In order to test vaccine efficacy in
swine, the protected rate as well as ID50 and the challenge
dose need to be determined. The OIE Manual of Diagnos-
tic Tests and Vaccines for Terrestrial Animals (OIE terres-
trial manual 2009, Chapter 2.1.5 Foot-and-mouth disease)
lists a number of criteria for testing FMD vaccines in pigs.
These include challenge in the heel bulb of 1 foot with 10
4
TCID50 of FMDV titered in a suitable pig cell culture sys-
tems or administering into one site of the muscular part
of the neck behind the ear. However, “challenge in the
heel bulb” is too laborious and time-consuming during the
commercial vaccine potency tests because more than hun-
dred pigs need to be captured at the same time, so we
choose “administering into one site of the muscular part
of the neck behind the ear” as our challenge route. Most
of the FMD vaccine companies in China select BHK-21
cell lines to propagate the swine vaccine virus strain, and
we also use BHK-21 passaged virus as the challenge strain
to keep the consistency. Unfortunately, we did not achieve
a good result in our factual operation due to the control
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any medium, provided the original work is properly cited.pigs not appear clinical symptoms while challenged intra-
muscularly with 10000 TCID50(TCID50 =8 . 0 ) ,w h i c h
means that the tests did not go on. Therefore we tried to
change the virus from cell-passaged strain to suckling
mice-passaged strain and hope to get a good result.
FMDV OH/99 strain was isolated from pigs [10] and
propagated in suckling mice as the challenge strain and
in baby hamster kidney (BHK-21) cells as the vaccine
strain. The suckling mice of 2-3-day-old were subcuta-
neously injected with 0.1 ml of OH/99 strain and passed
for 3-5 passages. Upon death (16-20 hr post-infection),
the bodies were collected and grinded.
Pigs median infected dose (PID50)w a sd e t e r m i n e d
with suckling mice’s passaged strain OH/99. The strain
was series decuple diluted from 10
-1 to 10
-10.F o r t y2 -
month-old pigs, sero-negative for FMDV antibodies,
were randomly divided into ten groups. Each group
including four pigs was housed in a separate room and
inoculated at the ear-root-neck area with 2 ml virus-
dilution per pig from 10
-1 to 10
-10 respectively. After ten
days clinical observation, the PID50 was calculated
according to Karber method. The experiment was
repeated for the dilutions 10
-5 to 10
-8.T h eP I D 50 was
calculated to be 6.5. The data were shown in Table 1.
The repeated data were the same.
The virus culture liquids were treated by ethylenim-
mine 0.035 M/L at 30°C during 24 h for virus inactiva-
tion, then the inactivation was stopped by 0.04 M
sodium thiosulphate [11]. Following the operation
guidelines, the inactivated FMDV antigen was emulsified
with Montanide ISA 206(Seppic, France)oil.
Sixteen 2-month-old pigs,s e r o - n e g a t i v ef o rF M D V ,
were intramuscular inoculated at the ear-root-neck area
with 2 ml inactivated vaccine respectively, and three
pigs were bred without vaccination in the same room as
negative control. Sera samples were collected at 14 dpv
(days post vaccination) and 28 dpv to assay the antibody
against FMDV serotype O using a standard LPB-ELISA
(Liquid phase blocking-ELISA).
To demonstrate vaccine efficacy, all 19 pigs were chal-
lenged intramuscularly with 1000 PID50/2 ml of FMDV
OH/99 suckling mice passaged strain at the ear-root-
neck area after 28 dpv and FMD symptoms were moni-
tored for 10 days.
T h er e s u l t so ft h ea n t i b o d yr e s p o n s et i t r a t i o n so f
14 dpv and 28 dpv of vaccinated pigs by LPB-ELISA and
protective effect in pigs were recorded in table 2. The
average titer at 14 dpv and 28 dpv was 1.50 and 1.84
respectively. At 2-4 days after challenge, blisters were
observed on three animals of the negative control group.
Sixteen vaccinated pigs were completely protected.
There are two prevention and eradication strategies
for FMD. “Slaughter policy” is definitely widely used in
the developed countries, but “vaccination policy” is
carried out in developing countries due to high FMD
prevalence and economic reasons. The FMD, in most
of the spontaneous epidemic areas, was found to
spread from cattle to cattle. However, in recent years,
pigs’ FMD circulated. China is one of the largest swine
breeding countries and pork plays a very important
role in people’s daily life. In view of the above men-
tioned arguments, the development of a cheap FMD
vaccine for swine is warranted and urgently needed.
After all, swine and cattle are different species, and
they have different immune system. The antibody
response level against FMDV type O in swine is lower
and weaker than which in cattle [12]. Normally, 10000
ID50 of virus challenge dose was used in cattle FMD
vaccine efficacy testing and 10000TCID50 was used in
pigs FMD vaccine efficacy testing (OIE terrestrial man-
ual 2009, Chapter 2.1.5 Foot-and-mouth disease).
However, in our experiments, 10000 ID50 dose was too
strong in pigs as even high efficient vaccines did not
protect the animals but 10000TCID50 was too weak in
pigs even 10
5 TCID50 only cause part of control pigs
occurring clinical signs, which was difficult to judge
the result’sc r e d i b i l i t yw h i l e“administering into one
site of the muscular part of the neck behind the ear
“(interior data). The pig’so r i g i n a lF M Dv i r u sw a s
stronger and could be used as the challenge strain, but
a large amount of the materials was limited to obtain.
The suckling mice passaged virus was used here as
challenge strain to solve the problem. Comparatively,
the suckling mice passaged virus was easier to propa-
gate, and the virulence equal to original virus but
stronger than BHK-21 passaged one, and infected all
control pigs in our repeatedly experiments. Therefore,
the suckling mice passaged virus was applied in our
intramuscular FMD vaccine potency test and a chal-
lenge dose was considered to be 1000 PID50.
Two of control pigs were arranged in OIE terrestrial
manual 2009. We found that sometimes one pig occurred
FMD clinical symptoms but another not while challenge
Table 1 Data for calculating PID50
Virus
dilution
Number of
pigs
Number of healthy
pigs
Number of sick
pigs
10
-1 40 4
10
-2 40 4
10
-3 40 4
10
-4 40 4
10
-5 40 4
10
-6 41 3
10
-7 43 1
10
-8 44 0
10
-9 44 0
10
-10 44 0
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Page 2 of 3even with original virus. The reason was not clear. But
h o wt oe v a l u a t et h ep o t e n c yt e s tw h e n1 / 2o fc o n t r o li s
p o s i t i v e ?S ow es e tt h r e ep i g sa sc o n t r o l .T h et e s tw i l lb e
appropriate when 2/3 of control pigs generated disease.
The antibody titer is one of referenced criteria to evalu-
ate vaccine potency as it is positively linked with protec-
tion rate, but it is influenced by factors such as vaccine’s
antigen content, animal’s individual status, virus chal-
lenge dose and route [13-15]. The LPB-ELISA assay was
recognized as one of the standard methods to detect anti-
body. The kit (bought from WRLforFMD, Britain) was
handled according to manufacture’si n s t r u c t i o n .W h e n
the titer is higher than 1.65, it means positive. Lower
than 0.6 means negative. The range from 0.78 to 1.65 is a
gray area, indicated that some animals can be protected,
others can not. In our result, only one pig’s( N o . 8 )a n t i -
body titer (1.34) of 28 dpv was lower than 1.65, which
belong to higher titer of gray area, and it was protected
in the challenge. Although these data criteria were desig-
nated to cattle, we referred it to pigs here.
However, the antibody titers could not instead of PD50
test. There are two ways to test FMD vaccine potency:
PD50 test(within Europe) or PG test (Protection against
Generalization [16]. Here, we accepted the ratio of vaccine
protection which used widely in South America. Sixteen
are vaccinated for 28 days, and other three are negative
control. The vaccine final products will be qualified when
the protected rate is equal or more than 12/16, and sick-
ness rate for control is equal or more than 2/3. Here, the
vaccine’s protection rate was 16/16.
From above, we measured pigs median infected dose
(PID50), used suckling mice passaged virus as intramuscu-
lar challenged strain, and determined 1000 PID50 as the
challenge dose to test the efficacy of swine FMD vaccine.
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Table 2 The results of the sera titers of 14 dpv and 28 dpv of vaccinated pigs by LPB-ELISA and protective effect in
swine challenged with OH/99
No. of pig 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
(Control)
18
(Control)
19
(Control)
Titer 14 dpv(-log10) 1.34 1.34 1.04 1.34 1.81 1.65 1.04 1.04 1.04 1.04 1.65 1.34 1.34 1.65 1.65 1.65 < 0.6 < 0.6 < 0.6
Titer 28 dpv(-log10) 1.81 1.95 1.65 1.81 2.25 2.11 1.65 1.34 1.65 2.11 1.95 1.81 1.95 1.81 2.11 1.81 < 0.6 < 0.6 < 0.6
Challenge P
a PPPPPPPPPPPPPPPU
b UU
a P means the pig was protected after challenge 28 dpv
b U means the pig was unprotected after challenge 28 dpv
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